Results 171 to 180 of about 293,399 (308)

Osteolysis After Interphalangeal Joint Arthrodesis in Systemic Sclerosis: A Case Series. [PDF]

J Rheumatol
Mathias KR, Grandison J, Lifchez SD, Wigley F.   +3 more
europepmc   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database

Arthritis &Rheumatology, EarlyView.
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro, Marie‐Elise Truchetet, Madelon Vonk, Giacomo De Luca, Giovanna Cuomo, Lidia P. Ananieva, Eric Hachulla, Vanessa Smith, Ana Maria Gheorghiu, Radim Becvar, Patricia Carreira, Nicolas Hunzelmann, Daniel E. Furst, Vera Ortiz‐Santamaria, Francesco Del Galdo, Marco Matucci‐Cerinic, Anna‐Maria Hoffmann‐Vold, EUSTAR collaborators   +17 more
wiley   +1 more source

Cognitive impairment, depression, and anxiety in systemic sclerosis. [PDF]

Front Med (Lausanne)
Szekanecz V, Lekli L, Bokor L, Kardos Z, Kardos VK, Hodosi K, Szamosi S, Szűcs G, Oláh C, Horváth Á, Molnár J, Szekanecz Z.   +11 more
europepmc   +1 more source

Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A European Multicenter Study

Arthritis &Rheumatology, EarlyView.
Objective Interstitial lung disease (ILD) can occur in association with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV‐ILD) or as an isolated entity with positive ANCA (ANCA‐ILD). However, data on the epidemiology and outcomes of these conditions remain limited.
Aglaia Chalkia, Marusa Kotnik, Timothy J. Sadler, Spyridon Katechis, Rachel Jones, Ajay Kamath, Aladdin J. Mohammad, Sara Monti, Chetan Mukhtyar, Viral Nanda, Ioannis Petrakis, Dimitrios Petras, Ashnish Sinha, Pasupathy Sivasothy, Rona Smith, Kostas Stylianou, Dimitrios Vassilopoulos, Judith Babar, David Jayne   +18 more
wiley   +1 more source

Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study [PDF]

, 2017
Alvarez, Enrique, Cross, Anne H, et al,
core   +2 more sources

Tissue‐Specific and Spatially Dependent Metabolic Signatures Perturbed by Injury in Male and Female Mice

Arthritis &Rheumatology, EarlyView.
Objective Osteoarthritis, the leading cause of disability worldwide, disproportionately affects women, yet sex remains an overlooked determinant. This disparity stems from sex‐specific differences in injury susceptibility—a major risk factor for disease.
Hope D. Welhaven, Avery H. Welfley, Priyanka P. Brahmachary, Mark Greenwood, Donald F. Smith, Brian Bothner, Ronald K. June   +6 more
wiley   +1 more source

Editorial: Systemic sclerosis: immunological impacts. [PDF]

Front Immunol
Komura K, Matsushita T.
europepmc   +1 more source

Long Noncoding RNA H19 Mediates STAT3‐Dependent Activation of Keratinocytes and Fibroblasts in Systemic Sclerosis Skin

Arthritis &Rheumatology, EarlyView.
Objective Dermal systemic sclerosis (SSc) fibroblasts and their exosomes can activate keratinocytes in SSc, with long noncoding RNA (lncRNA) H19 highlighted as the most up‐regulated RNA in their cargo compared with healthy controls (HCs). The role of H19 in SSc pathogenesis has never been investigated.
Begoña Caballero‐Ruiz, Christopher W. Wasson, Rebecca L. Ross, Francesco Del Galdo   +3 more
wiley   +1 more source

Anifrolumab-A Potential New Systemic Sclerosis Treatment. [PDF]

J Clin Med
Radić M, Prižmić PŠ, Bečić T, Đogaš H, Perković D, Radić J, Fabijanić D.   +6 more
europepmc   +1 more source